ASH 2020: Novel CAR-T Approaches Chase BCMA-Targeting Frontrunners

New Poseida Manufacturing Boosts Efficacy; Allogene Has First Allogeneic

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

BMS/bluebird and Janssen/Legend have the leading BCMA-targeting CAR-T therapies for multiple myeloma but Poseida, Allogene, CARsgen, Gracell and CBMG are emerging with novel approaches. 

BMS/bluebird's ide-cel is in the lead but many CAR-T approaches follow • Source: Shutterstock

Several companies presented results for next-generation B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor T-cell (CAR-T) therapies in relapsed or refractory multiple myeloma during the recent American Society of Hematology (ASH) meeting with early data that could give frontrunners Bristol Myers Squibb Company/bluebird bio and Janssen Pharmaceutical Cos./Legend Biotech Corp. a run for their money.

Allogene Therapeutics Inc. presented the first-ever clinical trial results at ASH for an off-the-shelf allogeneic BCMA-targeting CAR-T therapy –...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D